Presentation at ISPOR Europe, Nov. 2011, by Mark Sculpher, PhD, Professor of Health Economics, University of York, UK […]
Using Methods of Experimental Economics to Investigate Individual Determinants of Adherence and Implications for Mechanisms to Nudge Patients’ Behavior
Behnud Mir Djawadi, Research Associate, Department of Management, University of Paderborn, Paderborn, Germany; René Fahr, Full Professor, Department of Management, University of Paderborn, Paderborn, Germany; Florian Turk, Global Head, Health Economics & Outcomes Research, Critical Care Business […]
Using Net Benefits to Report Cost-Effectiveness Results, PPT by K. O
Presentation at ISPOR Europe, Nov. 2011, by Ken O'Day, PhD, Director, Xcenda, LLC, Palm Harbor, FL, USA; Denise Globe, PhD, Senior Director, Global Health Outcomes Strategy and Research, Allergan, LLC, Irvine, CA, USA […]
Accelerating the development of C-E Information: Does Phase IIIb represent an Opportunity
Marc L. Berger, MD, Executive Vice President & Senior Scientist, Life Sciences, OptumInsight, New York, NY, USA, ISPOR Washington DC, 2012. View presentation. […]
Use of Mapping to Estimate Health State Utility Values, PPT by L. Longworth
Presentation at ISPOR Europe, Nov. 2011 by Louise Longworth, PhD, Reader in Health Economics, Health Economics Research Group, Brunel University, Uxbridge, UK […]
The Appropriateness of the Cost Per QALY in the Decision Making Process, PPT by G. Oster
Presentation at ISPOR Europe, Nov. 2011, by Gerry Oster, PhD, Vice President, Policy Analysis Inc. (PAI), Brookline, MA, USA […]
Problems, pitfalls, and pragmatics of pharmacoeconomics: Lessons from Ghana
Martha Gyansa-Lutterodt, MA, MSc, Director of Pharmaceutical Services and Chief Pharmacist, Ghana Ministry of Health, Accra, Ghana, ISPOR Washington D.C. 2012. […]
The Appropriatemess of the Cost Per QALY in the Decision-Making Process, PPT by M. Nuijten
Presentation at ISPOR Europe, Nov. 2011, by Mark Nuijten PhD, MD, MBA, Consultant, Health Economics, Ars Accessus Medica, Amsterdam (Jisp), The Netherlands […]
Accelerating the development of CEA information: Does phase 3b represent an opportunity?
Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicines Agency, London, UK, ISPOR Washington DC, 2012. […]
Linking Existing Databases – Is It Worth the Pain?, PPT by R. LoCasale
Presentation at ISPOR Europe, Nov. 2011, by Robert J. LoCasale, PhD, MS, Senior Epidemiologist, Epidemiology, Merck, North Wales, PA, USA […]
Criteria for Value Assessment of Personalized Medicines , PPT by L. Annemans
Presentation at ISPOR Europe, Nov. 2011, by Lieven Annemans, PhD, MMan, MSc, Professor of Health Economics, I-CHER, Ghent University and Brussels University, Ghent, Belgium […]
Bridging the Gap in Data Collection Between Resource Use and Patient-Reported Outcomes
Presentation at ISPOR Europe, Nov. 2011, by Rob Thwaites, MA, Vice President, United BioSource Corporation, London, UK […]
Boost your health economics and outcomes research efforts
Gain instant access to detailed benchmarks and best practices that will streamline your health economics efforts. This one-of-a-kind study showcases the most up-to-date information on health economics and outcomes research (HEOR) goals and management. […]
Atlas of Variation 2011
The Atlas is published alongside the NHS Outcomes Framework to act as a catalyst for driving improvements in quality, outcome and value measurement throughout the NHS by encouraging a change in culture and behavior, including a renewed focus on tackling inequalities in outcomes. […]
Considerations About Evidence – Video Interviews
NPC asked the panelists for their insights on the challenges of developing and using evidence […]
How Comparative Effectiveness Feeds into Cost-Benefit Analysis by Kevin D. Frick PhD
The author relates CER to CBA, and discusses why CER research design is easier to translate into CBA than randomized controlled trials. […]
AHRQ: Development of Quality Criteria To Evaluate Nontherapeutic Studies of Incidence, Prevalence, or Risk Factors of Chronic Diseases: Pilot Study of New Checklists
Strategies for Conducting a Budget Impact Analysis at the MTF Level
This Powerpoint presentation which can be down loaded gives a brief overview of the concepts of Budget Impact Analysis (BIA). […]
Quality Assessment of Published Health Economic Analyses from South America
A PPT presentation examining South America's contribution. (Source: docstoc.com, Machado,M.et.al.) […]
Health outcomes analysis – Reliable answers to life
In the United States, we collect better quality information and provide more advanced analytics on baseball players than we do on our personal health. Every time a batter steps up to the plate or a kicker lines up for a field-goal attempt, the announcers have access to every possible statistic […]
Cost-of-Illness Studies: A Guide to Critical Evaluation
While COI studies attract much interest from public health advocates and healthcare policy makers, inconsistencies in the way in which they are conducted and a lack of transparency in reporting have made interpretation difficult, and have ostensibly limited their usefulness. (Source: AdisOnline.com, […]
Industry Experience of Multi-Stakeholder Early Advice Consultations, PPT by J. Anderson
Presentation at ISPOR Europe, Nov. 2011, by James S. Anderson, MA, MBA, European Partnerships Director, Government Affairs, Public Policy and Patient Advocacy, GlaxoSmithKline, Brentford, UK […]
Implications in Economic Analysis, PPT by P. McEwan
Presentation at ISPOR Europe, Nov. 2011, by Phil McEwan, PhD, Managing Director, HEOR Consulting, Monmouth, Monmouthshire, UK […]
External referencing and pharmaceutical price negotiation
External referencing (ER) imposes a price cap for pharmaceuticals, based on prices of identical or comparable products in foreign countries. This article describes a model that inspired by the wide European experience with this cost-containment policy. […]
Estimating the Effects of Consolidating Drugs under Part D or Part B
A recent report by Acumen, LLC, finds that consolidating Part B and Part D drug benefits would reduce Medicare's total payments by $150 million, which is 0.4% percent of total Part D drug costs. […]
Common errors that authors make when reporting the results of economic evaluations
In this YouTube video, the Editor of PharmacoEconomics discusses a common error authors make when reporting the results of economic evaluations(Source: Youtube) […]
Interview – Ulf Staginnus on European Cost-Containment Measures and Effects on Healthcare
Ulf Staginnus, is the creator of HealthEconomics Blog and Head Pricing, Health Economics & Outcome Research, Europe, at Novartis Oncology. He talks about the direct implications of recent European cost-containment measures on the pharmaceutical industry. Watch, and learn why the tough times are […]
A Model to TransferTrial-Based Pharmacoeconomic Analyses to Clinical Practice
This article deals with the question of how to handle costs to enhance medication adherence in trial-based pharmacoeconomic analyses. (Source: Pharmacoeconomics 2011) […]
A model to predict the cost-effectiveness of disease management programs
Article investigates a model to more accurately predict the impact of a disease management program on costs and cost-effectiveness. (Source: Health Economics, June 2010) […]
Definition of Health Economics from University of Groningen, The Netherlands.
Health economics is a sub-discipline of economics and studies the allocation of scarce resources among alternative healthcare programs or strategies for the promotion, maintenance and improvement of health. Health economics studies how healthcare and health-related services, their costs and […]
